MAP Publication

ISPOR 2019 – Copenhagen: Impact of conditional marketing authorisation and accelerated assessment on HTA outcomes

2019 |

In some circumstances the European Medicines Agency (EMA) grants interim marketing authorisations to promising products where collecting the required evidence within the normal regulatory timeframe is impractical. This study looks at the progress of these products through subsequent health technology assessment (HTA) and shows that faster approval does not appear to hinder these medicines access to reimbursement.


All Publications